✦ LIBER ✦

Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease

✍ Scribed by Choi, Grace K.H.; Collins, Stephanie D.E.; Greer, Daniel P.; Warren, Lisa; Dowson, Grace; Clark, Tanya; Hamlin, P. John; Ford, Alexander C.

Book ID: 122649915
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 324 KB
Volume: 8
Category: Article
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2013.09.017

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infliximab as first-line therapy for sev

Infliximab as first-line therapy for severe Crohn's disease?

✍ Dr. Russell D. Cohen; Charles N. Bernstein 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Infliximab as first-line therapy for Cro

Infliximab as first-line therapy for Crohn's disease is premature

✍ Dr. Gordon R. Greenberg 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Section editor's commentary. Infliximab

Section editor's commentary. Infliximab as first-line therapy for Crohn's disease

✍ Charles N. Bernstein 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Risk–benefit analysis of adalimumab vers

Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 474 KB 👁 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis

Budesonide recommended as first-line the

Budesonide recommended as first-line therapy for mild to moderate Crohn's disease

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

MA2 Comparison of Health Care Costs for

MA2 Comparison of Health Care Costs for Crohn's Disease Patients Who are Adherent Versus Intermittently Adherent with Infliximab Therapy

✍ B. Feagan; C. Kozma; T. Slaton; W. Olson; G. Wan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB